Subjects -> BIOLOGY (Total: 3174 journals)
    - BIOCHEMISTRY (239 journals)
    - BIOENGINEERING (143 journals)
    - BIOLOGY (1491 journals)
    - BIOPHYSICS (53 journals)
    - BIOTECHNOLOGY (243 journals)
    - BOTANY (233 journals)
    - CYTOLOGY AND HISTOLOGY (32 journals)
    - ENTOMOLOGY (67 journals)
    - GENETICS (165 journals)
    - MICROBIOLOGY (279 journals)
    - MICROSCOPY (13 journals)
    - ORNITHOLOGY (26 journals)
    - PHYSIOLOGY (73 journals)
    - ZOOLOGY (117 journals)


Showing 1 - 29 of 29 Journals sorted alphabetically
Acta Histochemica     Hybrid Journal   (Followers: 3)
Annals of Cytology and Pathology     Open Access   (Followers: 1)
Applied Immunohistochemistry & Molecular Morphology     Hybrid Journal   (Followers: 16)
Cell Discovery     Open Access   (Followers: 2)
Comparative Cytogenetics     Open Access   (Followers: 1)
Current Protocols in Cytometry     Hybrid Journal  
Cytogenetic and Genome Research     Full-text available via subscription   (Followers: 2)
Cytokine     Hybrid Journal   (Followers: 6)
Cytokine & Growth Factor Reviews     Hybrid Journal   (Followers: 3)
Cytokine : X     Open Access  
Cytology and Genetics     Hybrid Journal   (Followers: 4)
Cytometry Part A     Hybrid Journal   (Followers: 3)
Cytometry Part B: Clinical Cytometry     Hybrid Journal   (Followers: 4)
Cytopathology     Hybrid Journal   (Followers: 11)
Cytoskeleton     Hybrid Journal   (Followers: 1)
Cytotechnology     Hybrid Journal   (Followers: 10)
Diagnostic Cytopathology     Hybrid Journal   (Followers: 10)
Egyptian Journal of Genetics And Cytology     Open Access  
European Journal of Histochemistry     Open Access   (Followers: 4)
Folia Cryptogamica Estonica     Open Access  
Histochemistry and Cell Biology     Hybrid Journal   (Followers: 6)
Journal of Cytology & Histology     Open Access   (Followers: 5)
Journal of Histochemistry and Cytochemistry     Hybrid Journal   (Followers: 7)
Journal of Histotechnology     Hybrid Journal   (Followers: 2)
Journal of Molecular Histology     Hybrid Journal   (Followers: 5)
Journal of the American Society of Cytopathology     Hybrid Journal   (Followers: 5)
Journal of the History of Biology     Hybrid Journal   (Followers: 5)
Single Cell Biology     Open Access  
Vegetation History and Archaeobotany     Hybrid Journal   (Followers: 4)
Similar Journals
Journal Cover
Annals of Cytology and Pathology
Number of Followers: 1  

  This is an Open Access Journal Open Access journal
ISSN (Online) 2640-7809
Published by Peertechz Homepage  [75 journals]
  • Development of a management guidewheel for vulvar cancer

    • Abstract: Ismail’s Cancer Vulva Management Guidewheel is designed to enable physicians to refer to a quick and comprehensive reference to recommendations on the management of vulvar cancer at various stages. The wheel consists of patient characteristics, including the FIGO stage and the possible treatment modalities available along with alternatives. We compared guidelines on the management of vulvar cancer by international health organizations including the National Comprehensive Cancer Network (NCCN), the Society of Gynecologic Oncology (SGO), the European Society of Gynaecological Oncology (ESGO), the European Society of Urogenital Radiology (ESUR), the British Gynaecological Cancer Society (BGCS), the Royal College of Obstetricians and Gynaecologists (RCOG), the Japanese Society of Gynecologic Oncology (JSGO), the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the International Federation of Gynecology and Obstetrics (FIGO). Their respective recommendations have been compared and carefully integrated on the guidewheel.
      PubDate: 19 Jan, 2022
  • Diagnostic significance of combined immunohistochemical panel of p63, High
           Molecular Weight Cytokeratin (34betaE12) and α‑Methyl Acyl Co A
           Racemase (AMACR) in resolving suspicious foci in prostatic lesions

    • Abstract: Background: The assessment of small foci of atypical glands in prostatic needle biopsy specimens is a key diagnostic challenge in routine histopathology for pathologists. Due to the presence of mimickers of prostate carcinoma, at times making a definitive diagnosis becomes difficult. The use of immunomarkers like α‑Methyl Acyl Co A Racemase (AMACR), p63 and High Molecular Weight Cytokeratin (HMWCK/34betaE12) has made it easier for us to reach the diagnosis in such cases.Material and methods: All the cases which were received in the Department of Pathology, JNMCH, AMU from January 2015 to December 2018 were categorized into four histomorphologic groups on the basis of histopathology, and immunohistochemistry was applied on all the cases which were rendered ‘suspicious’ on histomorphology.Result: One hundred twenty-one prostatic specimens were received. Out of which, 13 biopsies were found to be inadequate for analysis and hence were not included in the study. Out of the rest 108 cases, (1) 52 were benign, (2) 19 were premalignant, (3) 25 were carcinoma and (4) 12 were signed as ‘suspicious’ on histopathology. These 12 suspicious cases were true cut needle biopsies which were considered appropriate for applying immunomarkers along with control cases. Out of 12 suspicious cases, 8 cases (66.7%) were negative and 3 cases (25%) were weakly positive for p63, 1 case showed moderate immunostaining. HMWCK was completely negative in 7 cases (58.33%), 3 cases (25%) showed weak positivity, 1 case showed moderate and 1 case showed strong positivity. While 5 cases (41.67%) were negative and 7 cases (58.33%) were positive for AMACR mostly showing moderate to strong positivityConclusion: The application of immunomarkers helped us to reach a definite diagnosis in 10 out of 12 cases, which were otherwise difficult to classify. Judicious use of immunomarkers can help in differentiating mimickers of prostate carcinoma from true cancer cases and assist in reaching a definitive diagnosis.
      PubDate: 10 Mar, 2022
  • Development of a management guide wheel for cervical cancer

    • Abstract: We designed and developed a management guide wheel for cervical cancer to facilitate a standard approach and improve the quality of care in managing patients diagnosed with different stages of cervical cancer. Each step of the wheel considers the patient’s current medical condition, FIGO stage, and the possible treatment modalities for cervical cancer in her case. We reviewed existing international guidelines on the management of cervical cancer and compared their respective recommendations. This guide wheel is based on recommendations by the following organizations: the National Comprehensive Cancer Network (NCCN), the Society of Gynecologic Oncology (SGO), the European Society of Gynaecological Oncology (ESGO), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the British Gynaecological Cancer Society (BGCS) and the International Federation of Gynecology and Obstetrics (FIGO).
      PubDate: 09 Feb, 2022
  • Evaluation of angiogenesis in cervical cancer using CD34 as a biomarker
           and its correlation with pathoanatomical features

    • Abstract: Aim: CD34 is an antigen found in hematopoietic progenitor cells and endothelial cells. Anti-CD34 antibody is a highly sensitive marker for neovascularisation and has also been studied as a marker for vascular tumours. However, there are few studies relating it to cervical carcinoma. The aim of our study is to evaluate the CD34 expression as a marker of angiogenesis in cervical cancer and to correlate the microvessel count and Microvessel Density (MVD) with histopathological type and grade of tumour and lymph node metastasis. Method: Total 75 malignant cases (65 cases of squamous cell carcinoma and 10 cases of adenocarcinoma) were stained with anti CD34 antibody to highlight the blood vessels. In each case, areas of highest neo-vascularization were identified using scanner lens. Blood vessels were counted in 10 microscopic fields at 400X magnification. Average number of non-canalized micro-vessels count per field was calculated (MVD).Result: The total number of microvessels stained per case ranged from 54 to 216. No statistically significant differences were observed for MVD with respect to the age of patient and histological type of carcinoma (p> 0.05). The mean vascular density in differentiated carcinoma and undifferentiated carcinoma, was 10.56 and 14.14 respectively. This clearly shows that the distribution of microvessels was higher among undifferentiated carcinomas, as compared to differentiated carcinoma (p < 0> 0.05).Conclusion: CD 34 can be used as a novel marker for estimation of MVD in cervical cancer, however further studies are required on large group of patients to establish its role as a therapeutic target against angiogenesis.
      PubDate: 29 Jun, 2021
  • PD-L1 testing in advanced stage lung cancer using cytology samples:
           Suitability and reporting issues. Comparison between two tertiary referral

    • Abstract: Background: Lung cancer is the most common cause of cancer-related death worldwide and unfortunately up to 80% of patients amongst newly diagnosed are inoperable therefore the cytological sample is often the only material available for diagnosis and assessment of molecular characteristics driving the treatment. Recently immunotherapy has shown promising results in tumors expressing Program Death Ligand 1 (PD-L1). The expression of PDL1 can routinely be detected by immunohistochemistry. However, the presence of several antibodies with different cut-off and the expression of this marker by normal immune cells are generating confusion in interpretation and the need for harmonization amongst pathologists.Materials and methods: We assessed the suitability of 74 consecutive cell blocks from cytology samples for PDL1 testing and evaluate the concordance between two different antibodies (Ventana assay SP263 and Dako 223C pharmDx assay) and amongst different pathologists from two different tertiary referral center for thoracic pathology. The degree of agreement was measured by Fleiss K statistic (FKS) for categorical scores after dichotomization based on specified cutoffs. A review of discordant cases was also performed.Results: Review of the slides stained with both antibodies showed substantial agreement within our department and moderate agreement with results from the other institution. Overall less than 10% of cases were deemed inadequate. Discordant cases showed a decreased amount of tumor cells, therefore, tumor heterogeneity could be responsible for the variation in the reading. Conclusions: Our results show overall concordance between the two antibodies and the suitability of cytology material for PDL-1 testing.
      PubDate: 25 Jan, 2021
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-